Gregory N Fuller, M.D., Ph.D.
Department of Pathology, Division of Pathology and Laboratory Medicine
Present Title & Affiliation
Primary Appointment
Professor, with Tenure, Department of Pathology, Division of Pathology & Laboratory Medicine, MD Anderson Cancer Center, Houston, TX
Chief, Section of Neuropathology, Department of Pathology, Division of Pathology/Lab Medicine, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1987 | Baylor College of Medicine, Houston, TX, USA, MD, Medicine |
| 1983 | University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA, PhD, Biomedical Science / Neuroscience |
Postgraduate Training
| 1990-1992 | Fellowship (Neuropathology), Duke University, Durham, NC |
| 1988-1990 | Residency (Anatomic Pathology), Duke University, Durham, NC |
| 1987-1988 | Internship (Pathology), Duke University, Durham, NC |
Board Certifications
| 1994 | American Board of Pathology, Combined Anatomic Pathology and Neuropathology |
Experience & Service
Administrative Appointments/Responsibilities
Co-Director, MDACC/Methodist-Cornell Neuropathology Fellowship, Department of MDACC-Methodist Hospital Neuropathology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - Present
Member, Executive Committee, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - Present
Director, Automated Image Analysis Core Laboratory, Department of Pathology, MD Anderson Cancer Center, Houston, TX, 2001 - Present
Institutional Committee Activities
Panel Member, WHO, International Brain Tumor Classification Working Group and Consensus Committee (Heidelberg), 2015 - Present
Member, PRS Executive Committee, 2014 - Present
Panel Member, WHO, ISN-Haarlem Colloquium to Guide Next Steps in Brain Tumor Classification, 2014 - Present
Member, Search Committee for Chair of the Department of Pathology, 2011 - 2012
Honors & Awards
| 2016 | Harlan J. Spjut Distinguished Pathologist Award, Houston Society of Clinical Pathologists |
| 2015 | Shields Warren Lecturship, Harvard Beth Israel Deaconess |
| 2015 | Fellows Award for Best Lecture, MD Anderson Cancer Center, Department of Pathology |
Selected Publications
Peer-Reviewed Articles
- Al Sannaa G, Watson KL, Olar A, Wang WL, Fuller GN, McCutcheon I, Torres KE, Lazar AJ. Sarcoma Brain Metastases: 28 Years of Experience at a Single Institution. Ann Surg Oncol 23(Suppl 5):962-967, 2016. e-Pub 2016. PMID: 27646022.
- Gressot LV, Doucette TA, Yang Y, Fuller GN, Heimberger AB, Bögler O, Rao A, Latha K, Rao G. Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer 136(9):2047-54, 2015. e-Pub 2014. PMID: 25302990.
- Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A 112(11):3421-6, 2015. e-Pub 2015. PMID: 25737557.
- Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P, International Society Of Neuropathology--Haarlem. International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading. Brain Pathol 24(5):429-35, 2014. e-Pub 2014. PMID: 24990071.
- Hightower E, Cabanillas M, Fuller GN, McCutcheon I, Hess K, Shah K, Waguespack S, Corley L, Devin J. Phospho-histone H3 (PHH3) Immuno-reactivity as a Prognostic Marker in Non-Functioning Pituitary Adenomas. Pituitary 15(4):556-61, 2012. PMID: 22120760.
- Lee I, Fox P, Ferguson S, Bassett R, Yuan Kong L, Schacherer C, Gershenwald JE,Grimm EA, Fuller GN, Heimberger A. The expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival 3(3):336-44, 2012. PMID: 22488042.
- Elllezam B, Theeler BJ, Walbert T, Mammoser A, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JB, Aldape KD. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grad II and III diffuse gliomas. Acta Neuropathol, 124(3):449-51, 2012. PMID: 22772980.
- Gottesfeld Z, Fuller GN , Wiggins RC. Adrenergic neuroplasticity is maintained in the nutritional rehabilitated adult rat. Experientia 37(2):168-9, 1981. PMID: 7238746.
- Taber KH, Fuller GN, Stanley JC, DeFrance JF, Wiggins RC. The effect of postnatal undernourishment on epileptiform kindling of dorsal hippocampus. Experientia 36(1):69-70, 1980. PMID: 7358137.
- Wiggins RC, Fuller GN, Astrello JM, Rigor BM. Decreased myelin synthesis in developing rats following repeated pre- and perinatal exposure to subanesthetic amounts of halothane. J Neurochem 33(1):361-3, 1979. PMID: 458464.
- Wiggins RC, Fuller GN, Bell ME. Incorporation of leucine metabolites into brain and sciatic nerve myelin. J Neurochem 32(5):1579-82, 1979. PMID: 438825.
- Wiggins RC, Fuller GN. Early postnatal starvation causes lasting brain hypomyelination. J Neurochem 30(6):1231-7, 1978. PMID: 670966.
- Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee WK, Zhang W. IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene 35(6):738-47. e-Pub 2016. PMID: 25893308.
- Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Do KA, Davis DW, Zhang Y, Smith L, Tamboli P, Tannir NM, Gombos DS, Fuller GN. Pilot Trial of Sunitinib Theraphy in Patients with von Hippel-Lindau Disease. Annals of Oncology.
Book Chapters
- Bell DA, Fuller GN, El-Naggar AK. The pathology of tumors and tumor-like lesions of the skull base. In: Comprehensive Management of Skull Base Tumors. 2nd Edition. New York: Thieme Publishers: New York, 2019.
- Fuller GN, Czerniak B and Dorfman H,. Neurogenous tumors and neurofibromatosis affecting bone. In: Dorfman and Czerniak’s Bone Tumors. 2nd ed. Czerniak, B: Milan, 2016.
Grant & Contract Support
| Title: | Implications of a novel glioblastoma classification defined by miR-21-Sox2 status |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | New Mechanisms of and Mouse Models for Medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Bullock Memorial Fund for Neurosurgery |
| Funding Source: | Anthony Bullock III Research Fund |
| Role: | Co-Principal Investigator |
| Title: | Validating the IGFBP2-ILK-NFkB pathway in glioma development and progression by a glial specific mouse model |
| Funding Source: | Goldhirsh Foundation |
| Role: | Co-Principal Investigator |
| Title: | Dissecting glioma genesis through a glial-specific mouse model (This is the renewal of the RO1 currently on no-cost extension) |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |